基于生物标志物的预测性富集在脓毒症危重患者研究中的应用:一项系统综述
该研究遵循PRISMA-ScR指南,检索OVID Medline、Embase和Cochrane Central Register of Controlled Trials数据库,纳入在成人脓毒症患者中使用分子生物标志物进行预测性富集的随机对照试验。共纳入12项研究,所有研究均使用血液来源的循环蛋白或脂多糖标志物进行预测性富集。5项研究(42%)报告主要终点有统计学显著影响,其中3项显示患者重要获益(降低死亡率或疾病严重程度),2项显示生物标志物相关替代终点改善。表现出获益的干预包括免疫、抗菌或凝血调节治疗,这些试验使用的生物标志物为suPAR、AT、mHLA-DR、IL-6和EAA。作者结论认为,尽管研究设计异质且数量有限,采用生物标志物富集策略的研究显示出提高临床试验效率的希望信号,仍需进一步探索、研究和验证。
要点
- 系统综述纳入12项在成人脓毒症患者中采用生物标志物预测性富集的RCT,5项(42%)报告主要终点显著改善。
- 5项获益试验中3项显示患者重要获益(降低死亡率或疾病严重程度),2项显示生物标志物相关替代终点改善。
- 表现出获益的干预包括免疫、抗菌或凝血调节治疗,所用生物标志物为suPAR、AT、mHLA-DR、IL-6和EAA。
- 所有纳入研究均使用血液来源的循环蛋白或脂多糖标志物进行预测性富集。
- 作者认为,基于生物标志物的预测性富集策略在重症试验设计中显示出提高效率的希望信号,但仍需进一步探索、研究和验证。
适用人群与场景
- 纳入:随机对照试验中 enrolled 的成人脓毒症患者。
- 场景:重症监护病房收治的脓毒症危重患者。
研究设计与关键结果
- 研究类型:系统综述,遵循PRISMA-ScR指南,检索OVID Medline、Embase和Cochrane Central Register of Controlled Trials数据库,共检索到1718条引文,最终纳入12项符合标准的RCT。
- 纳入研究特征:所有研究均使用血液来源的循环蛋白或脂多糖标志物进行预测性富集;采用叙述性总结,未进行统计合并;使用Cochrane Risk of Bias工具评估个体研究偏倚风险。
- 主要结果:12项研究中5项(42%)报告主要终点有统计学显著影响;其中3项显示患者重要获益(降低死亡率或疾病严重程度),2项显示生物标志物相关替代终点改善。
- 获益试验的干预与生物标志物:表现出获益的干预包括免疫、抗菌或凝血调节治疗;这5项试验使用的预测性富集生物标志物分别为suPAR、AT、mHLA-DR、IL-6和EAA。
证据类型、等级与局限
- 证据类型:系统综述(PRISMA-ScR指南),纳入12项RCT,采用叙述性总结,未进行统计合并。
- 偏倚风险评估:使用Cochrane Risk of Bias工具评估个体研究偏倚风险。
- 局限:原文报告研究设计异质且数量有限;作者结论指出基于生物标志物的预测性富集在重症试验设计中的应用仍需进一步探索、研究和验证。
对床旁实践的改变
- 作者认为,采用生物标志物预测性富集策略的试验显示出提高临床试验效率的希望信号,但该策略在重症试验设计中的应用仍需进一步探索、研究和验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis remains one of the most prevalent conditions necessitating admission to intensive care units and is associated with high mortality. Unfortunately, randomized trials examining therapeutics for critically-ill patients with sepsis have been disproportionately negative, failing to identify effective interventions, likely due to the dilution of treatment effects across highly diverse populations. Designing trials to identify patients that are most likely to benefit from an intervention based on biologic mechanism, known as predictive enrichment, may be an effective strategy for enhancing clinical trial efficacy. We conducted a systematic review to summarize the use of biological markers (biomarkers) used for predictive enrichment in randomized controlled trials (RCTs) including patients with sepsis.
METHODS: We conducted this review following PRISMA-ScR guidelines. We searched OVID Medline, Embase, and the Cochrane Central Register of Controlled Trials databases. We included RCTs that enrolled adult patients with sepsis that used molecular biomarkers for predictive enrichment in their study design. We summarize study characteristics, biomarkers used, predictive enrichment strategies, and trial outcomes narratively without statistical pooling. Risk of bias of individual studies was assessed using the Cochrane Risk of Bias tool.
RESULTS: Of the 1,718 citations found with the search, we included 12 eligible studies. All studies used either blood-based circulating proteins or lipopolysaccharide markers for predictive enrichment. Five studies (42%) reported statistically significant impacts on the primary outcome, with three showing patient-important benefit (reduced mortality or disease severity) and two demonstrating improvements in surrogate outcomes related to biomarkers. Interventions that demonstrated benefit included immune, antimicrobial or coagulation modulating therapies. These five trials that showed benefit used suPAR, AT, mHLA-DR, IL-6 and EAA as biomarkers for predictive enrichment.
CONCLUSIONS: This review characterizes the use of biomarkers for predictive enrichment in randomized trials of critically-ill patients with sepsis. Although the studies were heterogeneous in design and limited in number, those that employed biomarker-based enrichment strategies demonstrate a promising signal for enhanced clinical trial efficiency. The use of biomarkers for predictive enrichment in critical care trial design requires further exploration, investigation and validation.
参考来源
- Van Nynatten LR, Bokhary D, Wong MYS, et al. Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review. Crit Care. 2025. PMID: 41310736. doi:10.1186/s13054-025-05684-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。